Sociedad Americana de Hirudoterapia

Cloning, characterization, and heterologous expression of a candidate hirudin gene from the salivary gland transcriptome of Hirudo nipponia

Recombinant expression study published in Scientific Reports (2023)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryGenómica y proteómicaFarmacología salivalDesarrollo de fármacosShi P et al. · Scientific reports, 2023

Abstract

Hirudin is a pharmacologically active substance in leeches with potent blood anticoagulation properties. Although recombinant hirudin production isolated from Hirudo medicinalis Linnaeus and Hirudinaria manillensis Lesson is known, to our knowledge, this study is the first to report recombinant hirudin expression and production from Hirudo nipponia Whitman. Thus, the present study aimed to clone and characterize the full-length cDNA of a candidate hirudin gene (c16237_g1), which is localized on the salivary gland transcriptome of H. nipponia, and further evaluate its recombinant production using a eukaryotic expression system. The 489-bp cDNA possessed several properties of the hirudin "core" motifs associated with binding to the thrombin catalytic pocket. A fusion expression vector (pPIC9K-hirudin) was constructed and successfully transformed into Pichia pastoris strain GS115 via electroporation. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and western blot analysis confirmed hirudin expression. The recombinant protein was expressed with a yield of 6.68 mg/L culture. Mass spectrometry analysis further confirmed target protein expression. The concentration and antithrombin activity of purified hirudin were 1.67 mg/mL and 14,000 ATU/mL, respectively. These findings provide a basis for further elucidating the molecular anticoagulation mechanism of hirudin, and address China's growing market demand for engineered H. nipponia-derived hirudin and hirudin-based drugs.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsHirudinsAmino Acid SequenceDNA, ComplementaryTranscriptomeLeechesAnticoagulantsRecombinant ProteinsCloning, Molecular

Resumen

Identifies and recombinantly expresses a hirudin variant from Hirudo nipponia (Asian medicinal leech) — characterizes thrombin inhibition kinetics and structural features.

Por qué esto importa para la hirudoterapia

Researchers cloned and characterized a candidate hirudin gene from the salivary gland transcriptome of the medicinal leech Hirudo nipponia, achieving successful heterologous expression of the recombinant protein. The purified recombinant hirudin demonstrated potent antithrombin activity, establishing a viable biotechnological method to produce this key anticoagulant. For ASH's domain, this study directly addresses the growing pharmaceutical demand for engineered, leech-derived anticoagulants and elucidates the molecular mechanisms of hirudin. The main caveat is that the findings represent strictly preclinical, in-vitro biomanufacturing data; the abstract provides no clinical trials or in-vivo efficacy data for this specific H. nipponia derivative.

Citación

Cloning, characterization, and heterologous expression of a candidate hirudin gene from the salivary gland transcriptome of Hirudo nipponia.

Shi P et al. · Scientific reports, 2023

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.